232 related articles for article (PubMed ID: 1929760)
21. Persistence of cyclicity of the plasma dopamine metabolite, homovanillic acid, in neuroleptic treated schizophrenic patients.
Davila R; Zumarraga M; Andia I; Friedhoff AJ
Life Sci; 1989; 44(16):1117-21. PubMed ID: 2565009
[TBL] [Abstract][Full Text] [Related]
22. Evolution of plasma homovanillic acid (HVA) in chronic schizophrenic patients treated with haloperidol.
Galinowski A; Poirier MF; Aymard N; Leyris A; Beauverie P; Bourdel MC; Loo H
Acta Psychiatr Scand; 1998 Jun; 97(6):458-66. PubMed ID: 9669519
[TBL] [Abstract][Full Text] [Related]
23. Plasma catecholamine metabolites in schizophrenics: evidence for the two-subtype concept.
Chang WH; Chen TY; Lin SK; Lung FW; Lin WL; Hu WH; Yeh EK
Biol Psychiatry; 1990 Mar; 27(5):510-8. PubMed ID: 2310806
[TBL] [Abstract][Full Text] [Related]
24. Effects of haloperidol decanoate on plasma homovanillic acid in chronic schizophrenic patients.
Chang WH; Lin SK; Juang DJ; Chen LC; Yang CH; Lane HY; Jann MW
Biol Psychiatry; 1993 Apr; 33(7):557-9. PubMed ID: 8513043
[No Abstract] [Full Text] [Related]
25. Changes in symptoms and plasma homovanillic acid with amantadine hydrochloride in chronic schizophrenia.
Yamada K; Kanba S; Ohnishi K; Ashikari I; Yagi G; Asai M
Biol Psychiatry; 1997 May; 41(10):1062-4. PubMed ID: 9129786
[No Abstract] [Full Text] [Related]
26. Short-term haloperidol administration acutely elevates human plasma homovanillic acid concentration.
Davidson M; Giordani AB; Mohs RC; Horvath TB; Davis BM; Powchik P; Davis KL
Arch Gen Psychiatry; 1987 Feb; 44(2):189-90. PubMed ID: 3813816
[No Abstract] [Full Text] [Related]
27. Plasma homovanillic acid levels and subtyping of schizophrenia.
Chang WH; Chen TY; Lee CF; Hung JC; Hu WH; Yeh EK
Psychiatry Res; 1988 Mar; 23(3):239-44. PubMed ID: 3387499
[TBL] [Abstract][Full Text] [Related]
28. Plasma prolactin and homovanillic acid as markers for psychopathology and abnormal movements after neuroleptic dose decrease.
Newcomer JW; Riney SJ; Vinogradov S; Csernansky JG
Psychopharmacol Bull; 1992; 28(1):101-7. PubMed ID: 1609034
[TBL] [Abstract][Full Text] [Related]
29. Predicting haloperidol treatment response in chronic schizophrenia.
van Kammen DP; Kelley ME; Yao JK; Gilbertson MW; Gurklis JA; Inosaka T; Saito H; Peters JL; Sato M
Psychiatry Res; 1996 Aug; 64(1):47-58. PubMed ID: 8888364
[TBL] [Abstract][Full Text] [Related]
30. Apomorphine has no effect on plasma homovanillic acid in schizophrenic patients.
Davidson M; Kendler KS; Davis BM; Horvath TB; Mohs RC; Davis KL
Psychiatry Res; 1985 Oct; 16(2):95-9. PubMed ID: 3865258
[TBL] [Abstract][Full Text] [Related]
31. Relationships between interleukins, neurotransmitters and psychopathology in drug-free male schizophrenics.
Kim YK; Kim L; Lee MS
Schizophr Res; 2000 Sep; 44(3):165-75. PubMed ID: 10962218
[TBL] [Abstract][Full Text] [Related]
32. Plasma homovanillic acid in schizophrenics: supportive evidence for the two-subtype hypothesis.
Chen TY; Lee CF; Lung FW; Lee TC; Lin WL; Hu WH; Yeh EK; Chang WH
Taiwan Yi Xue Hui Za Zhi; 1989 Jun; 88(6):584-8. PubMed ID: 2571672
[TBL] [Abstract][Full Text] [Related]
33. First-episode neuroleptic-free schizophrenics: concentrations of monoamines and their metabolites in plasma and their correlations with clinical responses to haloperidol treatment.
Nagaoka S; Iwamoto N; Arai H
Biol Psychiatry; 1997 Apr; 41(8):857-64. PubMed ID: 9099412
[TBL] [Abstract][Full Text] [Related]
34. Plasma homovanillic acid levels and therapeutic outcome in schizophrenics: comparisons of neuroleptic-naive first-episode patients and patients with disease exacerbation due to neuroleptic discontinuance.
Akiyama K; Tsuchida K; Kanzaki A; Ujike H; Hamamura T; Kondo K; Mutoh S; Miyanagi K; Kuroda S; Otsuki S
Biol Psychiatry; 1995 Nov; 38(10):639-48. PubMed ID: 8555375
[TBL] [Abstract][Full Text] [Related]
35. Plasma homovanillic acid levels in first-episode schizophrenia. Psychopathology and treatment response.
Koreen AR; Lieberman J; Alvir J; Mayerhoff D; Loebel A; Chakos M; Amin F; Cooper T
Arch Gen Psychiatry; 1994 Feb; 51(2):132-8. PubMed ID: 7905259
[TBL] [Abstract][Full Text] [Related]
36. Haloperidol response and plasma catecholamines and their metabolites.
Green AI; Alam MY; Boshes RA; Waternaux C; Pappalardo KM; Fitzgibbon ME; Tsuang MT; Schildkraut JJ
Schizophr Res; 1993 Jun; 10(1):33-7. PubMed ID: 8369230
[TBL] [Abstract][Full Text] [Related]
37. Plasma homovanillic acid differences in clinical subgroups of first episode schizophrenic patients.
Baeza I; Castro-Fornieles J; Deulofeu R; de la Serna E; Goti J; Salvà J; Bernardo M
Psychiatry Res; 2009 Jul; 168(2):110-8. PubMed ID: 19501918
[TBL] [Abstract][Full Text] [Related]
38. Pharmacoclinical correlations in schizophrenic patients treated with haloperidol decanoate: clinical evaluations, concentrations of plasma and red blood cell haloperidol and its reduced metabolite, and plasma homovanillic acid.
Aymard N; Viala A; Stein I; Caroli F
Prog Neuropsychopharmacol Biol Psychiatry; 1995 Nov; 19(7):1119-35. PubMed ID: 8787036
[TBL] [Abstract][Full Text] [Related]
39. A comparison of plasma homovanillic acid in the deficit and nondeficit subtypes of schizophrenia.
Ribeyre JM; Lesieur P; Varoquaux O; Dollfus S; Pays M; Petit M
Biol Psychiatry; 1994 Aug; 36(4):230-6. PubMed ID: 7986887
[TBL] [Abstract][Full Text] [Related]
40. Schizophrenia, psychosis, and cerebral spinal fluid homovanillic acid concentrations.
Maas JW; Bowden CL; Miller AL; Javors MA; Funderburg LG; Berman N; Weintraub ST
Schizophr Bull; 1997; 23(1):147-54. PubMed ID: 9050120
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
